基线全身肿瘤负荷半自动评估作为新诊断前列腺癌68Ga-PSMA-11 PET/CT影像生物标志物
回顾性分析59例新诊断前列腺癌患者,半自动获取68Ga-PSMA-11 PET/CT全身PSMA肿瘤体积(wbPSMA-TV)和全身病灶总PSMA摄取(wbTL-PSMA)。两参数与PSA及Gleason评分显著相关,观察者内和观察者间一致性极佳(ICC均>0.990)。多因素分析显示wbTL-PSMA(HR 1.001,p=0.014)和Gleason评分(HR 5.124,p=0.031)可独立预测无进展生存期。
要点
- wbPSMA-TV和wbTL-PSMA半自动定量一致性极佳,观察者内和观察者间ICC均>0.990。
- wbTL-PSMA和Gleason评分是新诊断前列腺癌无进展生存期的独立预测因素。
- wbPSMA-TV与wbTL-PSMA均与PSA和Gleason评分显著相关(r=0.793~0.879)。
核心结论
- wbPSMA-TV和wbTL-PSMA作为影像生物标志物与临床特征显著相关。
- 高wbTL-PSMA或高Gleason评分与新诊断前列腺癌较短的无进展生存期独立相关。
研究设计与样本
- 回顾性分析59例新诊断前列腺癌患者。
- 采用68Ga-PSMA-11 PET/CT半自动获取全身肿瘤负荷参数wbPSMA-TV和wbTL-PSMA,并分析观察者内和观察者间可靠性。
- 参考标准为前列腺特异性抗原(PSA)值、Gleason评分及无进展生存期(PFS)。
诊断标准与关键数值
- wbPSMA-TV中位值32.6 cm3(范围1.0-3968.2 cm3),wbTL-PSMA中位值161.9(范围6.0-24971.7)。
- wbPSMA-TV与PSA的相关系数r=0.858(p<0.001),wbTL-PSMA与PSA的r=0.879(p<0.001)。
- wbPSMA-TV与Gleason评分的r=0.793(p<0.001),wbTL-PSMA与Gleason评分的r=0.805(p<0.001)。
- 单因素分析中,wbPSMA-TV、wbTL-PSMA、SUVmax、SUVpeak、SUVmean、原发灶PSMA-TV、原发灶TL-PSMA、fPSA和Gleason评分均为PFS的独立显著预测因素(均p<0.05)。
- 多因素分析中,wbTL-PSMA的HR为1.001(p=0.014),Gleason评分的HR为5.124(p=0.031),均可显著预测无进展预后。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The prognostic value of baseline tumor burden of prostate cancer was rarely studied. We aimed to evaluate the whole-body tumor burden of 68Ga- prostate specific membrane antigen-HBED-CC (68Ga-PSMA-11) PET/CT in newly diagnosed prostate cancer semi-automatically, and explore its preliminary application in predicting prognosis.
METHODS: Similar to metabolic tumor volume (MTV) and total lesion glycolysis (TLG) of 18F-FDG PET/CT, 68Ga-PSMA-11 PET/CT tumor burden parameters including whole-body PSMA tumor volume (wbPSMA-TV) and whole-body total lesions PSMA uptake (wbTL-PSMA) were acquired semi-automatically. The intra-observer and inter-observer reliability was analyzed. The relationship between tumor burden and prostate-specific antigen (PSA) value or Gleason score was investigated. The preliminary application of tumor burden in predicting progression-free survival (PFS) was explored.
RESULTS: Fifty-nine newly diagnosed prostate cancer patients were retrospectively analyzed. Semi-automatic quantification of whole-body tumor burden had excellent intra-observer and inter-observer consistency [all intra-class correlation coefficient (ICC) > 0.990]. wbPSMA-TV and wbTL-PSMA were 32.6 (range 1.0-3968.2) cm3 and 161.9 (range 6.0-24971.7), respectively. wbPSMA-TV and wbTL-PSMA correlated with PSA (r = 0.858, p < 0.001; r = 0.879, p < 0.001) and Gleason score (r = 0.793, p < 0.001; r = 0.805, p < 0.001) significantly. In univariate analysis, wbPSMA-TV, wbTL-PSMA, SUVmax, SUVpeak, SUVmean, PSMA-TV, TL-PSMA of primary tumor, fPSA and Gleason score were independent significant predictors of PFS (all p < 0.05). Moreover, in multivariate analysis, wbTL-PSMA [hazard ratio (HR): 1.001, p = 0.014] and Gleason score (HR: 5.124, p = 0.031) can significantly predict progression-free prognosis.
CONCLUSIONS: As imaging biomarkers, wbPSMA-TV and wbTL-PSMA correlated with clinical characteristics significantly. High wbTL-PSMA or Gleason score was associated with shorter PFS of newly diagnosed prostate cancer independently.
引用
- Zou Q, Jiao J, Zou MH, et al. Semi-automatic evaluation of baseline whole-body tumor burden as an imaging biomarker of 68Ga-PSMA-11 PET/CT in newly diagnosed prostate cancer. Abdom Radiol (NY). 2020. PMID: 32948911. doi:10.1007/s00261-020-02745-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。